- Report
- May 2024
- 138 Pages
Global
From €5947EUR$6,499USD£5,167GBP
- Report
- June 2024
- 200 Pages
Global
From €7275EUR$7,950USD£6,321GBP
- Report
- January 2022
- 60 Pages
Global
From €3615EUR$3,950USD£3,141GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1373EUR$1,500USD£1,193GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1830EUR$2,000USD£1,590GBP
- Report
- January 2022
- 60 Pages
Global
From €3615EUR$3,950USD£3,141GBP
- Clinical Trials
- December 2023
- 299 Pages
Global
From €2288EUR$2,500USD£1,988GBP
- Report
- August 2022
Global
From €723EUR$790USD£628GBP
- Report
- October 2023
- 93 Pages
Global
From €3500EUR$4,097USD£3,147GBP
- Report
- January 2022
- 97 Pages
Global
From €3200EUR$3,746USD£2,878GBP
- Report
- May 2022
- 43 Pages
Global
From €1830EUR$2,000USD£1,590GBP
- Report
- April 2022
- 50 Pages
Global
From €1830EUR$2,000USD£1,590GBP
Mucositis is a common side effect of chemotherapy and radiation therapy, and is characterized by inflammation and ulceration of the mucous membranes lining the digestive tract. Gastrointestinal drugs are used to treat the symptoms of mucositis, including pain, nausea, and diarrhea. These drugs can be administered orally, topically, or intravenously, depending on the severity of the condition. Commonly used drugs include antacids, proton pump inhibitors, and anti-inflammatory medications. Additionally, probiotics, prebiotics, and other nutritional supplements may be used to reduce inflammation and promote healing.
Companies in the mucositis drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
